PL372303A1 - Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania postaci I, VIII i IX soli hemi-wapniowej atorwastatyny - Google Patents

Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania postaci I, VIII i IX soli hemi-wapniowej atorwastatyny

Info

Publication number
PL372303A1
PL372303A1 PL03372303A PL37230303A PL372303A1 PL 372303 A1 PL372303 A1 PL 372303A1 PL 03372303 A PL03372303 A PL 03372303A PL 37230303 A PL37230303 A PL 37230303A PL 372303 A1 PL372303 A1 PL 372303A1
Authority
PL
Poland
Prior art keywords
calcium
processes
atorvastatin hemi
novel
forms
Prior art date
Application number
PL03372303A
Other languages
English (en)
Inventor
Limor Tessler
Judith Aronhime
Revital Lifshitz-Liron
Dalia Maidan-Hanoch
Nir Hasson
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of PL372303A1 publication Critical patent/PL372303A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL03372303A 2002-02-15 2003-02-19 Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania postaci I, VIII i IX soli hemi-wapniowej atorwastatyny PL372303A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35718102P 2002-02-15 2002-02-15
US42532502P 2002-11-12 2002-11-12

Publications (1)

Publication Number Publication Date
PL372303A1 true PL372303A1 (pl) 2005-07-11

Family

ID=27760457

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372303A PL372303A1 (pl) 2002-02-15 2003-02-19 Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania postaci I, VIII i IX soli hemi-wapniowej atorwastatyny

Country Status (14)

Country Link
EP (1) EP1480950A4 (pl)
JP (2) JP2005519076A (pl)
KR (1) KR100724515B1 (pl)
CN (1) CN100406436C (pl)
AU (1) AU2003217653A1 (pl)
CA (1) CA2475864A1 (pl)
DE (1) DE03713610T1 (pl)
ES (1) ES2241507T1 (pl)
HR (1) HRP20040768A2 (pl)
IS (1) IS7402A (pl)
MX (1) MXPA04007939A (pl)
NO (1) NO20043842L (pl)
PL (1) PL372303A1 (pl)
WO (1) WO2003070702A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
KR20090045420A (ko) 2002-02-19 2009-05-07 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화
EP1572643A2 (en) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CA2672554C (en) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
EP1711464A2 (en) * 2004-07-22 2006-10-18 Teva Pharmaceutical Industries Ltd Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
JP5523699B2 (ja) * 2005-04-08 2014-06-18 エギシュ ヂョヂセルヂャール ニルヴァーノサン ミケデ レースヴェーニタールササーグ 新規な結晶性のアトルバスタチンヘミカルシウム塩の多形相
DK1957452T3 (da) 2005-11-21 2010-07-26 Warner Lambert Co Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium
CA2633268A1 (en) 2005-12-13 2007-06-21 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US7915302B2 (en) 2007-03-02 2011-03-29 Dong-A Pharm. Co., Ltd. Crystal forms of pyrrolylheptanoic acid derivatives
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
KR101324862B1 (ko) * 2011-07-12 2013-11-01 (주)에이에스텍 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
CN105055357A (zh) * 2015-09-25 2015-11-18 青岛华之草医药科技有限公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
KR101723783B1 (ko) * 2017-02-24 2017-04-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1148049T1 (en) * 1995-07-17 2005-02-28 Warner-Lambert Company Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
DE60018100T2 (de) * 1999-11-17 2005-09-15 Teva Pharmaceutical Industries Ltd. Polymorphe form von atorvastatin-calcium
CA2391357C (en) * 1999-12-17 2009-01-06 Warner Lambert Research And Development Ireland Limited A process for producing crystalline atorvastatin calcium
ES2252088T3 (es) * 1999-12-17 2006-05-16 Pfizer Science And Technology Ireland Limited Procedimiento de produccion a escala industrial de la hemisal de calcio de la atorvastatina trihidrato cristalina.
IL155734A0 (en) * 2000-11-03 2003-11-23 Teve Pharmaceutical Ind Ltd Atorvastatin hemi-calcium form vii
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ES2319870T3 (es) * 2000-12-27 2009-05-14 Teva Pharmaceutical Industries Limited Formas cristalinas de atorvastatina.
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
HUP0400381A2 (hu) * 2001-06-29 2004-09-28 Warner-Lambert Company Llc [R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái
EE200400048A (et) * 2001-07-30 2004-04-15 Dr. Reddy's Laboratories Ltd. Atorvastatiinkaltsiumi kristalsed vormid VI ja VII
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
AU2002330735A1 (en) * 2002-09-03 2004-03-29 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
EP1572643A2 (en) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt

Also Published As

Publication number Publication date
WO2003070702A1 (en) 2003-08-28
AU2003217653A1 (en) 2003-09-09
ES2241507T1 (es) 2005-11-01
KR20040081202A (ko) 2004-09-20
EP1480950A1 (en) 2004-12-01
KR100724515B1 (ko) 2007-06-04
HRP20040768A2 (en) 2005-06-30
EP1480950A4 (en) 2005-05-18
CA2475864A1 (en) 2003-08-28
CN1646490A (zh) 2005-07-27
JP2009235083A (ja) 2009-10-15
NO20043842L (no) 2004-09-14
DE03713610T1 (de) 2005-10-20
CN100406436C (zh) 2008-07-30
MXPA04007939A (es) 2004-11-26
IS7402A (is) 2004-08-13
JP2005519076A (ja) 2005-06-30

Similar Documents

Publication Publication Date Title
PL372303A1 (pl) Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania postaci I, VIII i IX soli hemi-wapniowej atorwastatyny
HUP0600538A3 (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
PL377555A1 (pl) Nowe krystaliczne postaci soli hemi-wapniowej atorwastatyny i sposoby ich wytwarzania oraz nowe sposoby wytwarzania innych postaci
RS20130524A3 (en) PROCEDURE FOR OBTAINING AMINO CROTONYL UNITS
WO2003070725A3 (en) Process for preparing indolinone derivatives
WO2004113292A3 (en) Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
AU2003230457A1 (en) Compression of containers
AU2003253188A1 (en) Novel processes and intermediates for preparing triazolo-pyridines
PT1620396E (pt) Processo para a preparação de 2-cianopirrolidinas n-substituídas
IL180708A0 (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
AU2003297594A1 (en) Crystalline form f of atorvastatin hemi-calcium salt
AU2003216848A1 (en) Deracemisation of amines
IL173012A0 (en) Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin
AU2003225426A1 (en) Process for the preparation of urea
AU2003302645A1 (en) Synthesis of pyrrolidine compound and salt thereof
PL1685104T3 (pl) Sposoby wytwarzania N-podstawionych ftalimidów
HK1060294A (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2003238034A1 (en) Novel use of imidazotriazinones
AU2003235129A1 (en) Process for preparation of 2-aminoketones
AU2003200836A1 (en) Method for the preparation of matairesinol
AU2003296482A1 (en) Tetracyclines as anti-fungal agents for treatment of ringworm
GB2390088B (en) Combustion process for the preparation of LiCoVO4
LT2004018A (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2003271712A1 (en) Treatment of amm
AU2003274043A1 (en) Novel use of dioxocin-5-on derivatives

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)